BioAtla Investor Presentation Deck

Summary of Dosing Regimens for Phase 2 Clinical Studies with CAB-ROR2-ADC BA3021 Ozuriftamab Vedotin bicatla Indication NSCLC Melanoma Head and Neck Ovarian* *Investigator-initiated trial. NSCLC non small cell lung cancer Dose Q2W monotherapy Q2W in combo w/ nivolumab 3Q4W monotherapy Q2W monotherapy Q2W in combo w/ nivolumab Q2W monotherapy Q2W in combo w/ durvalumab Maximum Patient # N~ 20 N~ 20 N~ 20 N~ 20 N~ 20 N~ 40 N~ 20 BioAtla| Overview 33

View entire presentation